Meds Pipeline Monitor 2022 reviewed 1,257 new medicines

eAwazMedicine

Ottawa – The latest edition of the Patented Medicine Prices Review Board (PMPRB) Meds Pipeline Monitor reports that oncology continued to dominate the therapeutic mix of the drug pipeline in 2022, with cancer treatments representing nearly one third (30%) of medicines in all phases of clinical trials. Treatments for infectious diseases held the second largest share of the pipeline, at 15%, due …